The role of drugs in countering adverse pathophysiological profiles: influence on hemodynamics.
D000317:Adrenergic alpha-Antagonists / Q000494:pharmacology; D000319:Adrenergic beta-Antagonists / Q000494:pharmacology; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology; D000959:Antihypertensive Agents / Q000494:pharmacology*; D001581:Benzothiadiazines; D002121:Calcium Channel Blockers / Q000494:pharmacology; D004232:Diuretics; D006439:Hemodynamics / Q000187:drug effects*; D006801:Humans; D007741:Labetalol / Q000494:pharmacology; D005082:Physical Exertion; D012039:Regional Blood Flow / Q000187:drug effects; D049993:Sodium Chloride Symporter Inhibitors / Q000494:pharmacology
D000317:Adrenergic alpha-Antagonists; D000319:Adrenergic beta-Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D001581:Benzothiadiazines; D002121:Calcium Channel Blockers; D004232:Diuretics; D049993:Sodium Chloride Symporter Inhibitors; D007741:Labetalol